Table 1A. Hazards ratios of ASPN and BCR; for ASPN mRNA in Mortensen et al, and ASPN H-score in the McGill TMA. Cox analysis of ASPN mRNA and BCR in the Mortensen et al data set.
|
Univariate analysis |
Multivariate analysis |
||||||
|---|---|---|---|---|---|---|---|
| N (n) | HR | 95% CI | P-value | HR | 95% CI | P-value | |
| ASPN | 36 (22) | 2.16 | 1.30–3.59 | 0.003 | 2.23 | 1.32–4.66 | 0.009 |
| Gleason score | 36 (22) | 1.75 | 1.19–2.58 | 0.005 | 1.44 | 0.77–2.60 | 0.228 |
| PSA | 36 (22) | 1.07 | 1.03–1.12 | 0.001 | 1.08 | 1.02–1.14 | 0.005 |
| Stage | 33 (22) | 4.21 | 1.60–11.08 | 0.004 | 0.76 | 0.14–4.27 | 0.759 |
| Margin | 36 (22) | 3.70 | 1.51–9.03 | 0.004 | 2.39 | 0.57–10.04 | 0.236 |
| Age | 36 (22) | 0.99 | 0.91–1.08 | 0.842 | 0.95 | 0.86–1.05 | 0.295 |
Abbreviations: ASPN=asporin; BCR=biochemical recurrence; CI=confidence interval; HR=hazards ratio; PSA=prostate specific antigen; TMA=tissue microarray.
Cox proportional hazards ratio analysis showed that ASPN mRNA was predictive of BCR in both univariate (hazards ratio 2.16, P=0.003) and multivariate analysis (hazards ratio 2.23, P=0.009), in the Mortensen et al data set derived from microdissected normal and tumour tissue. ASPN mRNA showed a larger hazards ratio than Gleason grade in this data set. Bold indicates statistically significant values.